FDA Panel Voices Concerns Over Two Lymphoma Rushed Approvals

'The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway.'

Related Keywords

United States , University Of Cincinnati , Ohio , East Windsor , Massachusetts , Dana Farber Cancer Institute , Cincinnati , Columbus , Boston , Ohio State University , Oregon , Portland , Acrotech Biopharma , Ashish Anvekar , Tonik Choueiri , Andy Chen , Richard Pazdur , Bristol Myers Squibb , Alexandera Vinks , Ashley Rosko , Oregon Health Science University , Drug Administration , Harvard Medical School , Oncologic Drugs Advisory Committee Of The Food , Cincinnati Children Hospital Medical Center , Allos Therapeutics , Spectrum Pharmaceuticals , Oncologic Drugs Advisory Committee , Oregon Health , Science University , Cincinnati Children , Hospital Medical Center , Patient Safety , Lymphoma , Malignant Lymphoma , Cancer , Alignant Neoplasia , Arcinoma , Grant , Refractory , Adverse Effects , Side Effects , Hospitals ,